• Norovirus Hijacks NINJ1 for Selective Protein Secretion

  2026-05-01

  Song et al. reveal that murine norovirus (MNoV) co-opts the host cell protein NINJ1 to selectively secrete its NS1 protein via an unconventional pathway dependent on caspase-3 cleavage. This finding redefines our understanding of host-pathogen interactions and regulated plasma membrane rupture, with implications for the study of cell death signaling and viral immune evasion.

• Biotin-XX Tyramide Reagent: Precision Cell Surface Labeling

  2026-05-01

  Biotin-XX Tyramide Reagent empowers researchers to amplify signals with unmatched selectivity for cell surface proteins, enabling low-abundance detection without intracellular background. Its membrane-impermeant, HRP-catalyzed design sets a new benchmark for spatial proteomics, as showcased in studies of stem cell migration and inter-organ signaling.

• Strategic ROS Quantification: Elevating Translational Impact

  2026-04-30

  This thought-leadership article bridges mechanistic insight and strategic guidance for translational researchers seeking robust, reproducible measurement of reactive oxygen species (ROS) in live cells. Integrating recent breakthroughs—including the modulation of Nrf2 and EGFR/PI3K/AKT pathways in COPD by sulforaphane—with practical assay strategies, it highlights how precise ROS quantification underpins advances in oxidative stress, apoptosis, and disease modeling. The APExBIO Reactive Oxygen Species Assay Kit, leveraging the DCFH-DA fluorescent probe, is positioned as a critical tool enabling next-generation research.

• Itaconic Acid-Mediated TBK1 Inhibition Links Metabolism to I

  2026-04-30

  Chai et al. unveil how the IRG1-itaconic acid axis restrains excessive type I interferon (IFN-I) responses by alkylating TBK1 at Cys605, disrupting its activation. This mechanistic insight offers a metabolic feedback model for immune regulation and introduces itaconic acid-based TBK1 inhibitors as potential therapeutics for IFN-I-driven hyperinflammation.

• Mdivi-1: Selective DRP1 Inhibitor Transforming Apoptosis Ass

  2026-04-29

  Mdivi-1, a selective DRP1 inhibitor from APExBIO, enables precise dissection of mitochondrial fission and apoptosis in both cell and animal models. By integrating recent co-metabolomics insights, this guide outlines how to optimize your mitochondrial dynamics research, troubleshoot common pitfalls, and leverage novel workflow advances for neuroprotection and beyond.

• Meropenem Trihydrate: Benchmarks for Carbapenem Antibiotic R

  2026-04-29

  Meropenem trihydrate is a broad-spectrum carbapenem antibiotic with efficacy against gram-negative and gram-positive pathogens. It exhibits low MIC90 values and high stability for research workflows. Its metabolomic impact reveals critical insights into resistance phenotypes.

• SGI-1027 and Everolimus Synergy Via Lysosomal Membrane Perme

  2026-04-28

  This study demonstrates that combining the methuosis inducer SGI-1027 with everolimus enhances apoptosis and GSDME-dependent pyroptosis in renal cell carcinoma by triggering lysosomal membrane permeability. The findings reveal a novel mechanism for overcoming everolimus resistance and highlight lysosomal dynamics as a key therapeutic vulnerability.

• Caspofungin: Precision Antifungal Workflows for Candida Rese

  2026-04-28

  Caspofungin, a lipopeptide antifungal drug, empowers researchers to dissect β-(1,3)-D-glucan biosynthesis and tackle Candida resistance. This guide delivers evidence-driven workflows, protocol optimizations, and troubleshooting tips for reliable, reproducible antifungal research.

• Pol II Degradation Triggers Cell Death Beyond Transcription

  2026-04-27

  This article examines how degradation of RNA Polymerase II (Pol II) can activate cell death independently of transcriptional shutdown, as demonstrated in the referenced preprint. The findings reframe our understanding of DNA damage response and offer new directions for mechanistic cancer biology research.

• Capsaicin Beyond TRPV1: Epigenetic Modulation and Oncology I

  2026-04-27

  Explore how Capsaicin acts not only as a TRPV1 ion channel activator but as a potent KDM1A/LSD1 inhibitor, revealing new avenues in epigenetic cancer modulation. This article delivers a uniquely deep, evidence-driven analysis of Capsaicin’s dual mechanisms and translational value.

• ML133 HCl: Precision Potassium Channel Inhibition in Vascula

  2026-04-26

  ML133 HCl stands out as a highly selective potassium channel inhibitor, enabling targeted investigation of Kir2.1 function in cardiovascular and pulmonary artery smooth muscle cell research. Its robust specificity and reproducibility accelerate workflows and sharpen mechanistic insights into vascular remodeling and disease modeling.

• ATM Inhibition Promotes Macropinocytosis and Metabolic Adapt

  2026-04-25

  The referenced study uncovers how ATM kinase inhibition drives metabolic adaptation in cancer cells by inducing macropinocytosis. This mechanistic link reveals a metabolic vulnerability with implications for targeting nutrient acquisition pathways in ATM-deficient tumors.

• Spider Toxin v-Agatoxin-IVA Reveals Calcium Channel Diversit

  2026-04-24

  Sidach and Mintz's landmark study redefines the pharmacological selectivity of the spider toxin v-Agatoxin-IVA, demonstrating that its low-affinity blockade extends beyond classic P-type calcium channels to include N-type and Q-type currents in mammalian neurons. This nuanced pharmacological profiling has direct implications for both the classification of neuronal calcium channels and the design of selective neurophysiological experiments.

• Rucaparib (AG-014699): Precision PARP1 Inhibition in DNA Dam

  2026-04-24

  Rucaparib (AG-014699) empowers DNA damage response studies through unmatched PARP1 inhibition and radiosensitization, especially in PTEN-deficient cancer models. This guide details advanced workflows, optimization strategies, and practical troubleshooting to extract maximum value from APExBIO's high-performance reagent.

• Rosiglitazone (Brl-49653): Optimizing PPARγ Activation in Ad

  2026-04-23

  Rosiglitazone (Brl-49653) empowers metabolic researchers with precise, reproducible PPARγ activation, enabling advanced adipogenesis and insulin sensitivity studies. This guide translates recent breakthroughs—including functional rescue in rare PPARG variants—into actionable workflows and troubleshooting strategies.

15717 records 1/1048 page Next 12345 下5页 Last page